Table 1.
Variable | Non-DM | DM | P-value |
---|---|---|---|
(N=232) | (N=116) | ||
Age at Exam (years) | 66.6± 9.4 | 66.6± 9.4 | .98 |
Gender, n (%) | 98 (42%) | 49 (42%) | -- |
BMI of Patient | 28.8± 5.2 | 30.8± 5.5 | .001 |
BMI>30, n (%) | 84 (36%) | 58 (50%) | .01 |
Waist>102M, 88F, n(%) | 92 (40%) | 57 (49%) | .09 |
Metabolic Syndrome, n (%) | 54 (23%) | 62 (54%) | .001 |
Verified Hypertension, n(%) | 118 (51%) | 62 (53%) | .65 |
CAD (%) | 58 (25%) | 38 (33%) | .13 |
HF (n%) | 1 (0%) | 4 (3%) | .03 |
MI n,(%) | 20 (9%) | 17 (15%) | .09 |
Atrial Fib/Flutter n,(%) | 9 (4%) | 11 (9%) | .03 |
Stroke n,(%) | 5 (2%) | 2 (2%) | .79 |
Beta Blocker, n(%) | 59(27%) | 33 (29%) | .63 |
Calcium Channel Blocker, n(%) | 35 (16%) | 19 (17%) | .82 |
ACE Inhibitor, n(%) | 23 (10%) | 36 (32%) | <.001 |
Antilipemic Therapy, n(%) | 66 (30%) | 40 (35%) | .30 |
Total Cholesterol (mg/dL) | 199.9± 36.9 | 138.2± 20.4 | .04 |
LDL Cholesterol (mg/dL) | 125.9± 32.8 | 115.5± 32 | .005 |
Triglycerides (mg/dL) | 146.4± 79.6 | 183.2± 121.8 | <.001 |
HDL (mg/dL) <40M, <50F, n(%) | 122 (53%) | 83 (72%) | <.001 |
NT-proBNP (pg/mL), median (Q1, Q3) | 76.9 (32.3, 153.6) | 81.9 (31.8, 182.3) | .69 |
Aldosterone (pg/ml), median (Q1, Q3) | 5.6 (3, 8.7) | 4.9 (2.5, 8.6) | .52 |
Insulin (uU/mL), median (Q1, Q3) | 5.8 (4.1, 8.7) | 8.5 (5.1, 15.7) | <.001 |
Creatinine (mg/dL), median (Q1, Q3) | 0.9 (0.8, 1.0) | 0.9 (0.8, 1.0) | .63 |
SBP (mmHg) | 136.8± 22.2 | 138.2±20.4 | .56 |
DBP (mmHg) | 74.7± 10.6 | 72.3±8.5 | .04 |
Serum Glucose (mg/dL), median (Q1, Q3) | 95 (90, 102) | 130 (107,167) | <.001 |
ACE angiotensin-converting enzyme, BMI body mass index, CAD coronary artery disease, HF heart failure, DBP diastolic blood pressure, MI myocardial infarction, HDL high-density lipoprotein, LDL low-density lipoprotein, NT-proBNP n-terminal pro hormone b-type natriuretic peptide, SBP systolic blood pressure
dL deciliter, mg milligram, mmHg millimeters of mercury, Pg picogram, uU international units